Polyneuropatie jako následek protinádorové léčby

Title in English Chemotherapy-induced peripheral neuropathy


Year of publication 2019
Type Article in Periodical
Magazine / Source Onkologická revue
MU Faculty or unit

Faculty of Medicine

Web https://onkologickarevue.cz/cs/polyneuropatie-jako-nasledek-protinadorove-lecby
Keywords polyneuropathy; chemotherapy; antineuralgic therapy; platinum derivatives; vinca alkaloids; taxanes
Description Chemotherapy-induced polyneuropathy (CIPN) is a very common side effect of antitumor therapy, which fundamentally affects the quality of life of patients, and may lead to the need for dose reduction or modification of the antitumor therapy schedule. Most patients experience regression or complete resolution of clinical symptoms over time, but in some individuals clinical symptoms may persist over the long term. The most prominent neurotoxic agents include platinum derivatives, taxanes, vinca alcoloids, proteasome complex inhibitors (bortezomib) and thalidomide. In particular, CIPN affects sensitive nerves, and rarely autonomic or motor symptoms such as postural hypotension or muscle weakness are encountered. The development of CIPN can be prevented by the correct indication of neurotoxic treatment. It is particularly appropriate to take into account pre-existing neuropathy or the existence of its risk factors. At the same time, the condition of the peripheral nervous system should be monitored regularly during treatment and, when clinical symptoms occur, reduce neurotoxic therapy or change the treatment regimen.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info